BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
Portfolio Pulse from
BeyondSpring presented updated efficacy results from a Phase 2 IIT study at the 39th SITC Annual Meeting. The study involved a triple IO combo of Pembrolizumab, Plinabulin, and Docetaxel in metastatic NSCLC patients who had progressed on prior immune checkpoint inhibitors. The regimen showed a Disease Control Rate (DCR) of 89.3% and a Median Progression-Free Survival (PFS) of 8.6 months.
November 11, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BeyondSpring's Phase 2 study results for a triple IO combo in metastatic NSCLC patients show promising efficacy, potentially boosting investor confidence.
The positive efficacy results from BeyondSpring's study could lead to increased investor confidence and interest in the company's stock, as the promising data may enhance the perceived value of their drug pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90